Description: EyePoint Pharmaceuticals, Inc., a specialty biopharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases. The company's lead product is ILUVIEN for the treatment of diabetic macular edema; and product candidate is YUTIQ, a non-erodible fluocinolone acetonide insert for the treatment of non-infectious posterior uveitis that is in the Phase III clinical trials. It also offers Retisert (fluocinolone acetonide intravitreal implant), a sustained-release implant for the treatment of posterior segment uveitis. In addition, the company has developed DEXYCU (dexamethasone intraocular suspension), an intraocular product for the treatment of postoperative ocular inflammation; and Vitrasert (ganciclovir), a sustained release implant for the treatment of cytomegalovirus retinitis. Further, it develops YUTIQ shorter-actinguveitis for the treatment of posterior segment uveitis; and Durasert tyrosine kinase inhibitor for the treatment of wet age-related macular degeneration. Additionally, the company's development program focuses on developing sustained release products using its Durasert and Verisome technology platforms to deliver drugs to treat chronic diseases. It sells its products primarily in the United States and Europe. The company has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, and Enigma Therapeutics Limited. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was founded in 1987 and is headquartered in Watertown, Massachusetts.
Home Page: eyepointpharma.com
EYPT Technical Analysis
480 Pleasant Street
Watertown,
MA
02472
United States
Phone:
617 926 5000
Officers
| Name | Title |
|---|---|
| Ms. Nancy S. Lurker | Pres, CEO & Director |
| Mr. George O. Elston | Chief Financial Officer |
| Dr. Jay S. Duker M.D. | Chief Operating Officer |
| Mr. David Scott Jones | Sr. VP & Chief Commercial Officer |
| Mr. Said Saim | Chief Technology Officer |
| Mr. Ron I. Honig Esq. | Chief Legal Officer & Company Sec. |
| Mr. Michael Pine | Chief Corp. Devel. & Strategy Officer |
| Ms. Jennifer Leonard | Chief People Officer & Sr. VP of IT |
| Dr. Dario A. Paggiarino | Sr. VP & Chief Medical Officer |
| Ms. Isabelle Lefebvre | Chief Regulatory Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.7274 |
| Price-to-Sales TTM: | 2.1535 |
| IPO Date: | 2005-01-27 |
| Fiscal Year End: | December |
| Full Time Employees: | 122 |